Benign Prostatic Hyperplasia (BPH)

1. Clinical Overview

Summary

Benign Prostatic Hyperplasia (BPH) is the histological diagnosis describing non-malignant proliferation of epithelial and stromal cells within the prostate gland. This is an almost universal feature of male aging, with prevalence increasing from approximately 50% at age 60 to over 90% by age 85. [1,2]

The clinical cascade involves four distinct but related entities:

• BPH (Benign Prostatic Hyperplasia): Histological diagnosis - cellular proliferation
• BPE (Benign Prostatic Enlargement): Anatomical diagnosis - palpable/measurable gland enlargement
• BOO (Bladder Outflow Obstruction): Functional diagnosis - impaired urine flow
• LUTS (Lower Urinary Tract Symptoms): Clinical diagnosis - patient-reported symptoms

Importantly, these do not always coexist: patients may have histological BPH without symptoms, or LUTS without demonstrable prostatic enlargement. [3]

Management is stratified by symptom severity (IPSS score), degree of bother, and presence of complications. Treatment options range from conservative measures through pharmacotherapy (α-blockers, 5α-reductase inhibitors) to surgical intervention (TURP, HoLEP, minimally invasive techniques). [4,5]

Clinical Pearls

High Pressure Chronic Retention (HPCR): The "Silent Kidney Killer"

These patients present with a massively distended bladder (often > 1L residual volume) but are completely pain-free due to detrusor desensitization. The critical danger is bilateral hydronephrosis with progressive renal impairment. The bladder pressure exceeds the ureteric peristaltic pressure, causing back-transmission to the renal pelvis.

Management Priorities (web/content/topics/bph-adult.mdx:44):

• Catheterize immediately (relieve obstruction)
• NEVER leave patient unmonitored
• Measure hourly urine output meticulously
• Post-obstructive diuresis risk: > 200ml/hr for 2+ hours
• Replace 50% of previous hour's urine output as IV crystalloid
• Monitor U&Es daily (rapid changes in urea/creatinine/potassium)
• Urology referral for definitive management

PSA Interpretation Pitfalls (web/content/topics/bph-adult.mdx:52)

BPH raises PSA predictably: approximately 0.15 ng/mL per gram of prostatic tissue. However, multiple confounders exist:

• Ejaculation: Elevated for 48 hours
• Cycling/Exercise: Can raise PSA acutely
• Prostatitis/UTI: Massive elevations (wait 6 weeks post-treatment)
• Digital Rectal Examination: Controversial - gentle DRE unlikely to affect significantly
• 5α-Reductase Inhibitors: Reduce PSA by approximately 50% after 6 months (must double reported value)

Always use age-specific reference ranges:

• Age 40-49: 0-2.5 ng/mL
• Age 50-59: 0-3.5 ng/mL
• Age 60-69: 0-4.5 ng/mL
• Age 70-79: 0-6.5 ng/mL

Intraoperative Floppy Iris Syndrome (IFIS) (web/content/topics/bph-adult.mdx:66)

Tamsulosin (and other α-blockers) cause irreversible changes to the iris dilator muscle. During cataract surgery, this manifests as:

• Billowing, floppy iris
• Pupillary constriction during surgery
• Iris prolapse through incisions

Increases complication rates significantly. Always ask about upcoming ophthalmic surgery before starting α-blockers. If cataract surgery planned within 6-12 months, consider delaying tamsulosin or using alternative (5-ARI, or refer directly to surgery). Alert the ophthalmologist if patient already on α-blocker.

TUR Syndrome (web/content/topics/bph-adult.mdx:75)

Historically a feared complication of monopolar TURP using glycine irrigation. Absorption of hypotonic irrigation fluid through opened prostatic venous sinuses causes:

• Hyponatraemia: Acute dilutional (less than 120 mmol/L)
• CNS symptoms: Confusion, seizures, coma
• Cardiovascular collapse
• Visual disturbances (glycine is neurotoxic to retina)

Modern Prevention: Bipolar TURP uses normal saline irrigation, virtually eliminating this risk. However, fluid overload remains possible with prolonged resection (> 90 minutes).

---

2. Epidemiology

Prevalence and Incidence

BPH is the most common benign tumor in men. Histological prevalence increases exponentially with age: [1,2]

Clinical Impact: [3]

• Approximately 30% of men over 50 have bothersome LUTS
• Annual incidence of acute urinary retention: 3-4 per 1000 men aged 60-69, rising to 10 per 1000 in men over 80
• Lifetime risk of surgical intervention for BPH: approximately 20-30%

Demographic Variations

Racial Differences: [6]

• African-American men: Higher prevalence, earlier onset, more severe symptoms, larger prostates
• Asian men: Lower prevalence compared to Western populations
• Caucasian men: Intermediate prevalence

Geographic Variation:

• Higher rates in Western countries
• Association with Western dietary patterns (high fat, low fiber)

Risk Factors

Non-Modifiable: [7]

• Age: Strongest predictor (essential for BPH development)
• Family history: 2-4x increased risk with first-degree relative affected
• Genetic factors: Androgen receptor polymorphisms
• Ethnicity: African ancestry increases risk

Modifiable: [8,9]

• Metabolic Syndrome: Obesity, diabetes, hypertension all associated
  • Central obesity increases risk by 3.5x
  • Diabetes associated with larger prostates
• Diet: High-fat, high-protein, low-fiber diets
• Physical inactivity: Sedentary lifestyle increases risk
• Inflammation: Chronic prostatitis may accelerate BPH

Protective Factors:

• Regular exercise (reduces risk by ~25%)
• Mediterranean diet pattern
• Phytoestrogen consumption (controversial)

---

3. Aetiology and Pathophysiology

Hormonal Mechanisms

Exam Detail: The development of BPH is fundamentally an androgen-dependent process, but the precise molecular mechanisms remain incompletely understood. The current paradigm involves:

1. Dihydrotestosterone (DHT) - The Key Driver

Testosterone (T) is converted to dihydrotestosterone (DHT) by the enzyme 5α-reductase, which exists in two isoforms:

• Type 1: Predominantly in liver, skin
• Type 2: Predominantly in prostate (especially stromal cells), genital skin

DHT has approximately 10-fold higher affinity for the androgen receptor (AR) compared to testosterone. [10]

Within prostatic cells:

1. DHT binds nuclear androgen receptors
2. DHT-AR complex translocates to nucleus
3. Binds androgen response elements (AREs) on DNA
4. Upregulates growth factor expression:
   • FGF (Fibroblast Growth Factor)
   • EGF (Epidermal Growth Factor)
   • IGF (Insulin-like Growth Factor)
5. Inhibits apoptosis (cell death pathway blocked)
6. Stromal-epithelial interactions perpetuate growth

Result: Net accumulation of cells (hyperplasia), not increased cell size (hypertrophy).

2. Estrogen's Role

The estrogen-androgen ratio changes with aging:

• Testosterone levels decline (~1% per year after age 40)
• Estradiol levels remain relatively stable (aromatization of androgens)
• Increased estrogen sensitizes prostate to DHT
• Estrogen may upregulate androgen receptors

This creates a "permissive environment" for DHT-driven growth. [11]

3. Prostatic Aging and Stem Cells

Current theory suggests prostatic stem cell dysregulation:

• Aged prostatic stem cells fail to differentiate properly
• Aberrant reactivation of embryonic developmental pathways
• Imbalance between proliferation and programmed cell death

Anatomical Zones and Clinical Correlation

The prostate is divided into distinct anatomical zones (McNeal classification): [12]

Clinical Importance (web/content/topics/bph-adult.mdx:187):

• BPH arises almost exclusively in the transition zone (periurethral region)
• This explains why even small prostates can cause significant LUTS (directly compress urethra)
• Prostate cancer arises mainly in peripheral zone (explains why DRE detects cancer - posterior peripheral zone is palpable)
• A man can have a large benign transition zone (LUTS from BPH) AND peripheral zone cancer simultaneously

Pathophysiological Components of Obstruction

BPH causes bladder outflow obstruction through two distinct mechanisms: [13]

1. Static Component (~50% of obstruction)

The mechanical bulk of the hyperplastic nodules:

• Physical compression of prostatic urethra
• Median lobe can project into bladder neck ("ball-valve" effect)
• Enlargement distorts urethral anatomy
• Increased urethral length and tortuosity

2. Dynamic Component (~50% of obstruction)

Active muscular contraction of prostatic smooth muscle:

• Prostatic stroma contains abundant α₁-adrenoceptors (predominantly α₁A subtype)
• Sympathetic nervous system activation → smooth muscle contraction
• Increased bladder neck and prostatic urethral tone
• Exacerbated by stress, anxiety, cold

Clinical Relevance:

• Explains why symptoms fluctuate (dynamic component varies with sympathetic tone)
• Provides rationale for α-blocker therapy (targets dynamic component)
• Provides rationale for 5α-reductase inhibitors (targets static component by shrinking gland)
• Combination therapy addresses both components

Bladder Response to Obstruction

Chronic bladder outflow obstruction triggers a cascade of compensatory and decompensatory changes: [14]

Phase 1: Compensation (Reversible)

• Detrusor hypertrophy: Increased muscle mass (like cardiac hypertrophy)
• Increased contractility to overcome resistance
• Trabeculation (visible muscle bundles on cystoscopy)
• Bladder wall thickening

Phase 2: Decompensation (Partially Reversible)

• Detrusor overactivity: Unstable contractions (storage symptoms)
• Collagen deposition (fibrosis)
• Decreased compliance (stiff bladder)
• Sacculation and diverticulum formation

Phase 3: End-Stage (Irreversible)

• Detrusor failure: Acontractile bladder
• Massive bladder capacity (> 1L)
• Chronic retention with overflow
• Back-pressure effects on kidneys

Urodynamic Correlates:

• Early: High-pressure voiding, normal compliance
• Middle: Detrusor overactivity, reduced compliance
• Late: Low-pressure chronic retention, high post-void residual

---

4. Clinical Presentation

Lower Urinary Tract Symptoms (LUTS)

LUTS are conventionally divided into three categories: [15]

Storage Symptoms (Irritative)

Mnemonic: FUN

• Frequency
• Urgency
• Nocturia

Voiding Symptoms (Obstructive)

Mnemonic: WISE-PT

• Weak stream
• Intermittency
• Straining
• Emptying incomplete
• Prolonged voiding
• Terminal dribbling

Post-Micturition Symptoms

Symptom Severity Assessment

International Prostate Symptom Score (IPSS): [16]

The IPSS is a validated 7-question questionnaire, each scored 0-5 (total 0-35):

Additional QoL Question: "If you were to spend the rest of your life with your urinary symptoms the way they are now, how would you feel?" (0-6 scale)

• Bother score often guides treatment more than IPSS alone
• Patient with IPSS 15 but "delighted" may not need treatment
• Patient with IPSS 10 but "mostly dissatisfied" may benefit from intervention

Physical Examination

General Examination

• Abdominal Palpation: Palpable bladder (suprapubic dullness to percussion)
  • "Chronic retention: Non-tender, may be massive (up to umbilicus)"
  • "Acute retention: Tender, tense, patient in distress"
• Peripheral Edema: Suggests high-pressure chronic retention with renal failure
• Neurological Exam: If neurogenic bladder suspected (lower limb tone, reflexes, saddle anesthesia)

Digital Rectal Examination (DRE)

Essential for every patient with LUTS. Systematic assessment: (web/content/topics/bph-adult.mdx:309)

Size Estimation:

• Normal: ~20g (walnut-sized)
• Grade I: 20-30g (small egg)
• Grade II: 30-50g (large egg)
• Grade III: 50-100g (small orange)
• Grade IV: > 100g (large orange)

Note: DRE significantly underestimates true gland size (palpates mainly posterior peripheral zone, not central transition zone where BPH arises)

Consistency:

• BPH: Smooth, elastic, rubbery ("bouncy")
• Cancer: Hard, stony, craggy ("rock-like")
• Prostatitis: Tender, boggy

Surface:

• BPH: Smooth, regular margins
• Cancer: Nodular, irregular, asymmetric

Median Sulcus:

• BPH: May be preserved or obliterated (doesn't distinguish from cancer)
• Loss of sulcus suggests larger gland

Lateral Sulci:

• Should be palpable (separates prostate from levator ani)

Mobility:

• Normally mobile
• Fixed suggests locally advanced cancer with extracapsular extension

---

5. Differential Diagnosis

LUTS in men is not synonymous with BPH. Systematic consideration of alternatives is essential: [17]

Special Considerations

Young Men (less than 50 years) with LUTS:

• BPH very uncommon - consider alternatives first
• Urethral stricture (post-STI, trauma)
• Chronic prostatitis/chronic pelvic pain syndrome
• Neurogenic causes
• Overactive bladder

LUTS + Hematuria:

• Red flag - excludes from "simple BPH" pathway
• Mandatory exclusion of bladder/upper tract malignancy
• Requires cystoscopy ± CT urogram

LUTS + Renal Impairment:

• High-pressure chronic retention until proven otherwise
• Urgent renal imaging (ultrasound for hydronephrosis)
• Catheterize if retention confirmed

---

6. Investigations

Baseline (All Patients)

Urinalysis (Dipstick)

Purpose: Exclude infection, hematuria

• Leucocytes/Nitrites: UTI (send culture)
• Blood: Hematuria (red flag - requires cystoscopy ± imaging)
• Protein: Possible renal impairment
• Glucose: Screen for diabetes (polyuria mimic)

Interpretation: Negative dipstick does not exclude bladder cancer (cytology-negative tumors exist). Visible hematuria requires full investigation regardless of negative dipstick.

Serum Creatinine & eGFR

Purpose: Detect obstructive uropathy

• Chronic high-pressure retention causes bilateral hydronephrosis
• May present with advanced CKD
• Indications for renal imaging:
  • Elevated creatinine
  • Palpable bladder
  • Large post-void residual (> 300ml)
  • Nocturia ≥3 times per night

Frequency-Volume Chart (Bladder Diary)

Purpose: Quantify symptoms objectively (3-day diary)

Records:

• Time of each void
• Volume voided
• Fluid intake
• Incontinence episodes

Key Metrics:

• 24h urine volume: Normal 1000-2000ml (> 3000ml = polyuria)
• Nocturnal polyuria: > 33% of 24h output overnight
• Functional bladder capacity: Largest single void
• Frequency: Voids per 24h (normal less than 8)

Clinical Use:

• Distinguishes polyuria from frequency
• Identifies nocturnal polyuria (treat with desmopressin, not prostate surgery)
• Detects excessive fluid intake

Prostate-Specific Antigen (PSA)

Controversial but widely offered to informed men > 50 years (or > 45 if high risk). [18]

PSA Counseling (Essential Before Testing)

What is PSA?

• Prostate-specific antigen is a serine protease produced by prostatic epithelium
• NOT cancer-specific: elevated in BPH, prostatitis, UTI, prostate cancer
• Small amounts leak into bloodstream

Reasons PSA May Be Elevated: (web/content/topics/bph-adult.mdx:430)

• Prostate cancer (~15% of men with PSA 4-10 have cancer on biopsy)
• BPH (~0.15 ng/mL per gram of tissue)
• Prostatitis/UTI (massively elevated - wait 6 weeks)
• Ejaculation (elevated for 48h)
• Vigorous exercise (cycling)
• Urinary retention

Consequences of Testing:

• Anxiety from abnormal result
• May lead to prostate biopsy (10% infection risk, 1% sepsis, pain, hematuria)
• May detect indolent cancers that would never cause harm (overdiagnosis)
• May also detect significant cancers that benefit from early treatment

After counseling, patient decides whether to proceed.

Age-Specific Reference Ranges

Further PSA Metrics

PSA Density (PSAD):

• PSAD = PSA (ng/mL) ÷ Prostate volume (mL)
• PSAD > 0.15 suggests cancer more likely than BPH
• Requires prostate volume measurement (TRUS or MRI)

Free:Total PSA Ratio:

• PSA exists as free PSA and PSA bound to proteins
• Free:Total ratio less than 20% suggests cancer
• Free:Total ratio > 25% suggests BPH
• More useful in PSA "gray zone" (4-10 ng/mL)

PSA Velocity:

• Rate of PSA rise over time
• > 0.75 ng/mL per year concerning

PSA Doubling Time:

• Used mainly in post-treatment surveillance

PSA and 5α-Reductase Inhibitors

Critical: Finasteride/dutasteride reduce PSA by ~50% after 6 months of treatment.

• When interpreting PSA in a patient on 5-ARI: Double the reported value
• Example: Patient on finasteride for 1 year has PSA 2.5 ng/mL → true PSA equivalent is ~5.0 ng/mL
• Any rise in PSA while on 5-ARI is suspicious for cancer

Specialist Investigations

Uroflowmetry

Non-invasive measurement of urinary flow rate

Patient voids into a commode that measures flow continuously.

Key Parameters:

• Qmax (Maximum flow rate):
  • "> 15 mL/s: Normal"
  • "10-15 mL/s: Equivocal (may be normal in older men, or mild obstruction)"
  • "less than 10 mL/s: Suggests obstruction"
• Voided volume: Must be > 150ml for valid result (low volumes give falsely low Qmax)
• Flow curve morphology:
  • "Normal: Bell-shaped curve"
  • "Obstruction: Prolonged, flattened curve"
  • "Stricture: Plateau pattern"

Limitations:

• Does not distinguish obstruction from detrusor weakness (both give low flow)
• Affected by voided volume, patient anxiety, technique

Post-Void Residual (PVR)

Measurement of bladder volume immediately after voiding (bladder ultrasound)

Thresholds:

• less than 50 mL: Normal
• 50-100 mL: Borderline (acceptable in elderly)
• 100-200 mL: Abnormal (mild retention)
• 200-300 mL: Moderate retention
• > 300 mL: Significant retention
• > 500 mL: High risk of complications

Clinical Significance:

• Predicts progression and retention risk
• PVR > 200ml associated with 3x risk of acute urinary retention
• Guides surgical candidacy

Variability: PVR varies significantly between voids (repeat if borderline)

Prostate Volume Measurement

Transrectal Ultrasound (TRUS):

• Measures prostate dimensions (length × width × height)
• Volume calculated: 0.52 × L × W × H (ellipsoid formula)
• Guides treatment selection (large glands > 80g may need HoLEP or open prostatectomy)

MRI Prostate:

• More accurate than TRUS
• Used if cancer suspected (mpMRI)

Clinical Use:

• Small (less than 30g): Consider alternative diagnoses (stricture, neurogenic)
• Moderate (30-80g): Standard TURP appropriate
• Large (> 80g): HoLEP or open prostatectomy

Urodynamics (Pressure-Flow Studies)

Invasive test combining cystometry with flowmetry

Indications (not routine): [19]

• Diagnostic uncertainty (LUTS but small prostate)
• Young men (less than 50 years)
• Neurological disease
• Previous failed surgery
• Considering surgery but equivocal obstruction

Measurements:

• Detrusor pressure at Qmax (PdetQmax): > 40 cmH₂O suggests obstruction
• Bladder Outlet Obstruction Index (BOOI): PdetQmax - 2×Qmax
  • "BOOI > 40: Obstructed"
  • "BOOI less than 20: Unobstructed"
  • "BOOI 20-40: Equivocal"

Findings:

• Distinguishes obstruction from detrusor underactivity
• Identifies detrusor overactivity
• Assesses compliance

Flexible Cystoscopy

Direct endoscopic visualization of urethra, prostate, bladder

Indications:

• Hematuria (exclude bladder cancer)
• Suspected stricture
• Previous pelvic surgery/radiotherapy
• Atypical symptoms
• Pre-operative assessment for TURP

Findings in BPH:

• Lateral lobe enlargement (narrowed prostatic urethra)
• Median lobe (projects into bladder - "ball valve")
• Trabeculation (bladder muscle hypertrophy)
• Diverticula (bladder wall pouches)
• Bladder stones (from stasis)

---

7. Classification and Scoring Systems

International Prostate Symptom Score (IPSS)

The gold standard symptom score, identical to the American Urological Association Symptom Index (AUA-SI). [16]

Seven Questions (Each Scored 0-5)

Total Score: 0-35

Quality of Life Question (QoL)

"If you were to spend the rest of your life with your urinary condition the way it is now, how would you feel?"

Clinical Use: QoL score ≥4 (mostly dissatisfied) suggests patient-driven need for intervention regardless of IPSS.

---

8. Management

General Principles

Management is individualized based on:

1. Symptom severity (IPSS)
2. Degree of bother (QoL score)
3. Complications (retention, renal impairment, stones, recurrent UTI, hematuria)
4. Patient preference (some prefer tablets, others want definitive surgery)
5. Prostate size (large glands may need specific surgery)
6. Co-morbidities (fitness for surgery, medications)

Management Algorithm

                LUTS Suggestive of BPH
                         ↓
        ┌────────────────┴────────────────┐
        ↓                                 ↓
   COMPLICATIONS?                    NO COMPLICATIONS
   (Retention, Renal                      ↓
   Impairment, Stones,              Assess IPSS + QoL
   Recurrent UTI,                         ↓
   Refractory Hematuria)       ┌──────────┼──────────┐
        ↓                      ↓          ↓          ↓
   SURGERY INDICATED      IPSS 0-7   IPSS 8-19  IPSS 20-35
        ↓                   Mild      Moderate   Severe
   See Surgical              ↓          ↓          ↓
   Options Below      QoL less than 4?    Trial Medical  Medical Rx
                      Reassure   Therapy        Fail?
                      Watchful        ↓              ↓
                      Waiting    Effective?     SURGERY
                                      ↓
                              YES: Continue
                              NO: Surgery

Conservative Management

Watchful Waiting (Active Surveillance)

Indications: [20]

• Mild symptoms (IPSS 0-7)
• Low bother (QoL score less than 4)
• No complications

Components:

• Patient education (natural history, reassure benign process)
• Lifestyle modifications:
  • "Fluid management: Avoid excessive fluid intake (especially evening)"
  • "Caffeine reduction: Bladder irritant (coffee, tea, cola)"
  • "Alcohol reduction: Diuretic + bladder irritant"
  • "Timing of fluids: Front-load hydration to morning/afternoon"
  • "Double voiding: Void, wait 1 min, attempt second void"
  • "Avoid bladder irritants: Spicy foods, artificial sweeteners"
• Medication review: Avoid anticholinergics, α-agonists (decongestants), diuretics if possible
• Treat constipation: Straining worsens LUTS
• Bladder retraining: Scheduled voiding, urge suppression techniques

Monitoring: Annual review (IPSS, DRE, consider PSA if baseline abnormal)

Outcome: 30-40% stable or improve over 5 years; 20-30% eventually require intervention.

---

9. Medical Therapy

Three main pharmacological classes used: [4,5]

α₁-Adrenoceptor Antagonists (α-Blockers)

Mechanism of Action:

• Block α₁A-adrenoceptors in prostatic smooth muscle (stromal tissue) and bladder neck
• Reduces smooth muscle tone → decreased dynamic component of obstruction
• Does not reduce prostate size

Agents: (web/content/topics/bph-adult.mdx:681)

Efficacy: [21]

• IPSS improvement: 30-40% reduction (4-6 points)
• Qmax improvement: 20-25% increase (1.5-3 mL/s)
• Onset: Rapid (within days to 2 weeks)
• Response: ~60-70% of men experience improvement

Side Effects:

• Postural hypotension/dizziness: 5-10% (especially non-selective agents) - advise "first-dose effect," take at bedtime
• Retrograde ejaculation: 5-10% (semen enters bladder, harmless but may distress patient - "dry orgasm")
• Intraoperative Floppy Iris Syndrome (IFIS): Risk during cataract surgery (inform ophthalmologist)
• Nasal congestion: α₁ receptors in nasal mucosa
• Asthenia/fatigue: 5%

Contraindications:

• Postural hypotension
• Planned cataract surgery (relative - discuss with ophthalmologist)

Monitoring:

• Assess response at 4-6 weeks (IPSS)
• Blood pressure (especially in first weeks)

5α-Reductase Inhibitors (5-ARI)

Mechanism of Action:

• Inhibit 5α-reductase enzyme → block conversion of testosterone to DHT
• Reduces prostate volume by 20-30% over 6-12 months
• Targets static component of obstruction
• Also reduces prostate vascularity (reduces hematuria risk)

Agents: (web/content/topics/bph-adult.mdx:720)

Efficacy: [22]

• IPSS improvement: 30-35% reduction (similar to α-blockers, but takes months)
• Qmax improvement: 1.5-2 mL/s increase
• Prostate volume reduction: 18-28% reduction over 6-12 months
• Onset: Slow (3-6 months for symptoms; 6-12 months for maximal effect)
• Progression prevention: Reduces risk of acute retention by ~50%, reduces surgery risk by ~50% [22]

Indications: (web/content/topics/bph-adult.mdx:739)

• Moderate-severe LUTS (IPSS ≥8)
• Large prostate (> 40g / > 30 mL) - most benefit
• High PSA (> 1.5 ng/mL)
• Recurrent hematuria from BPH (reduces vascularity)
• Prevention of progression (especially if risk factors: age > 70, PSA > 1.5, prostate > 40g)

Side Effects: [23]

• Sexual dysfunction (10-15%):
  • Erectile dysfunction
  • Reduced libido
  • Ejaculatory disorders (reduced volume)
• Gynecomastia (1-2%)
• Breast tenderness
• Depression (controversial; reports of persistent symptoms post-discontinuation)

Important Counseling Points:

• PSA reduction: Expect ~50% reduction after 6 months - must double PSA value for cancer risk interpretation
• Pregnancy: Teratogenic (causes ambiguous genitalia in male fetus) - women of childbearing age must not handle crushed tablets
• Time to effect: Patience required (3-6 months)
• Long-term therapy: Lifelong to maintain effect

Contraindications:

• Pregnancy (partner of male patient)
• Women and children (no indication)

Combination Therapy (α-Blocker + 5-ARI)

Rationale: Targets both dynamic (α-blocker) and static (5-ARI) components

Evidence: [24,25]

MTOPS Trial (Medical Therapy of Prostatic Symptoms):

• N=3047 men, 4.5 years follow-up
• Doxazosin + Finasteride vs. monotherapy vs. placebo
• Combination reduced risk of clinical progression by 66% (vs. 39% doxazosin alone, 34% finasteride alone)
• Clinical progression = IPSS increase ≥4, AUR, renal insufficiency, recurrent UTI, incontinence

CombAT Trial (Combination of Avodart and Tamsulosin):

• N=4844 men with LUTS, prostate > 30g, PSA 1.5-10 ng/mL
• Dutasteride + Tamsulosin vs. monotherapy
• Combination superior for symptom improvement (especially in large prostates > 40g)
• Reduced long-term AUR and surgery risk

Indications: (web/content/topics/bph-adult.mdx:784)

• Moderate-severe LUTS (IPSS ≥8)
• Large prostate (> 40g)
• High risk of progression (PSA > 1.5, age > 70, previous AUR)
• Patient wants to avoid/delay surgery

Commercially Available Combinations:

• Combodart: Dutasteride 500 mcg + Tamsulosin 400 mcg (single capsule, once daily)

Strategy:

• Start combination from outset, OR
• Add 5-ARI to patient already responding to α-blocker (to prevent progression), OR
• Add α-blocker to patient on 5-ARI for faster symptom relief

Duration:

• Some discontinue α-blocker after 6-12 months (once 5-ARI effect established), continuing 5-ARI alone
• Others continue combination long-term

Other Medical Therapies

Phosphodiesterase-5 Inhibitors (PDE5i): (web/content/topics/bph-adult.mdx:802)

• Tadalafil 5 mg OD (Cialis Once Daily) licensed for LUTS/BPH
• Mechanism: Smooth muscle relaxation (bladder, prostate, vasculature)
• Efficacy: Modest IPSS improvement (2-3 points)
• Use: Mainly in men with LUTS + erectile dysfunction (dual benefit)
• Side effects: Headache, dyspepsia, flushing, nasal congestion
• Contraindication: Nitrates (risk of severe hypotension)

Anticholinergics/Antimuscarinics:

• Used for overactive bladder (storage symptoms)
• Traditionally avoided in BOO (risk of retention)
• Can be used cautiously in men with predominant storage symptoms, adequate flow, low PVR
• Examples: Solifenacin, tolterodine
• Combination α-blocker + antimuscarinic for mixed LUTS

β₃-Agonists:

• Mirabegron (Betmiga) 50 mg OD
• Relaxes detrusor muscle (storage symptoms)
• Alternative to antimuscarinics (fewer anticholinergic SEs)
• Safe in BPH if adequate flow

Phytotherapy (Plant Extracts):

• Saw palmetto (Serenoa repens): Popular but no consistent evidence of efficacy [26]
• Not recommended in guidelines

---

10. Surgical and Interventional Therapy

Indications for Surgery

Absolute Indications (failure of conservative/medical management not applicable): [27]

• Refractory urinary retention (failed trial without catheter)
• Recurrent urinary retention
• Renal insufficiency due to BOO (high-pressure chronic retention)
• Bladder stones due to BOO
• Recurrent UTIs due to BOO
• Recurrent gross hematuria refractory to 5-ARI

Relative Indications (patient/physician preference):

• Bothersome LUTS refractory to medical therapy
• Patient preference for surgery (to avoid lifelong medication)
• Intolerance to medications (side effects)
• Large post-void residual (> 300-400 mL)

Transurethral Resection of Prostate (TURP)

The traditional "Gold Standard" - endoscopic resection of transition zone.

Technique:

• Spinal or general anesthesia
• Resectoscope passed transurethrally
• Electrocautery loop ("cutting diathermy") sequentially resects "chips" of prostatic tissue
• Hemostasis with "coagulating diathermy"
• Continuous irrigation (traditionally glycine; now normal saline with bipolar)
• Chips sent for histology (exclude cancer)
• Catheter for 24-48h

Efficacy: [28]

• IPSS improvement: 70% reduction (~15 points)
• Qmax improvement: 100-125% increase (doubles flow rate)
• Durability: 80-90% satisfied at 5 years; 10-20% re-operation rate at 10 years

Indications:

• Moderate-large prostates (30-80g)
• Failed medical therapy or patient preference

Complications: (web/content/topics/bph-adult.mdx:870)

Monopolar vs. Bipolar TURP:

• Monopolar: Glycine irrigation (hypotonic) → TUR syndrome risk
• Bipolar: Normal saline irrigation → virtually eliminates TUR syndrome; increasingly preferred

Holmium Laser Enucleation of Prostate (HoLEP)

Laser enucleation of entire transition zone (analogous to open prostatectomy but endoscopic).

Technique:

• Holmium:YAG laser used to enucleate entire adenoma
• Enucleated tissue morcellated (minced) within bladder, then aspirated
• Tissue sent for histology

Efficacy: [29]

• Equivalent or superior to TURP for symptom improvement and flow rates
• Durability: Lower re-operation rates than TURP (more complete adenoma removal)

Advantages over TURP:

• Large prostates: Can treat prostates > 100g (TURP difficult/prolonged)
• Less bleeding: Better for anticoagulated patients
• Shorter catheter time: 12-24h (vs. 24-48h TURP)
• Lower re-operation rate
• Saline irrigation (no TUR syndrome)

Disadvantages:

• Steep learning curve (operator-dependent)
• Longer operative time initially (improves with experience)
• Equipment cost
• Limited availability

Complications: Similar to TURP (retrograde ejaculation 75%, transient incontinence, stricture)

Indications:

• Large prostates (> 80-100g) - particularly suited
• Anticoagulation (safer)
• Patient preference

Open Prostatectomy

Surgical enucleation of adenoma via open incision (retropubic or suprapubic approach).

Indications:

• Very large prostates (> 100-120g) where HoLEP unavailable
• Concomitant bladder pathology requiring open surgery (e.g., large bladder diverticulum, bladder stones)

Techniques:

• Retropubic (Millin): Incision through anterior prostatic capsule
• Suprapubic (Freyer): Incision through bladder, then through posterior bladder neck

Efficacy: Excellent symptom relief (equivalent to HoLEP)

Disadvantages:

• Invasive (laparotomy)
• Longer hospital stay (5-7 days)
• Longer catheter time (5-7 days)
• Higher morbidity than endoscopic surgery
• Retrograde ejaculation (80%)

Modern Role: Declining (replaced by HoLEP); reserved for very large glands when HoLEP unavailable.

Minimally Invasive Surgical Therapies (MIST)

Alternative techniques for men seeking:

• Symptom relief without general anesthesia
• Preservation of ejaculatory function
• Faster recovery
• Willing to accept potentially lower efficacy/durability than TURP

Prostatic Urethral Lift (UroLift)

Permanent implants that retract lateral lobes ("hold curtains open").

Technique:

• Local anesthetic + sedation
• Cystoscopy
• Implants deployed via urethra
• Small tabs anchor in prostatic capsule; sutures retract lobes laterally
• Typically 4-6 implants

Efficacy: [30]

• IPSS improvement: 30-50% reduction (moderate)
• Qmax improvement: 20-50% increase
• Durability: Data to 5 years (some symptom recurrence; ~10-15% require re-treatment)

Advantages:

• Preserves ejaculatory function (~90% retain antegrade ejaculation) - key advantage
• Day-case procedure (local anesthetic)
• Rapid recovery
• Minimal bleeding

Disadvantages:

• Less effective than TURP/HoLEP for severe symptoms or large prostates
• Not suitable for median lobe (implants only retract lateral lobes)
• Durability uncertain beyond 5 years
• Symptoms of irritation first few weeks

Indications:

• Moderate LUTS (not severe)
• Small-moderate prostates (less than 80g)
• No median lobe
• Patient prioritizes ejaculatory preservation
• Unfit for general anesthesia

Rezum (Water Vapor Thermal Therapy)

Transurethral delivery of water vapor (steam) causing thermal ablation of prostatic tissue.

Technique:

• Local anesthetic
• Steam injections into transition zone via transurethral device
• Thermal energy causes immediate cell necrosis
• Tissue resorbed over 3 months

Efficacy: [31]

• IPSS improvement: 40-50% reduction
• Qmax improvement: 50% increase
• Durability: Data to 5 years (sustained benefit)

Advantages:

• Office-based procedure (local anesthetic)
• Can treat median lobe (unlike UroLift)
• Preserves ejaculatory function in ~75%
• Minimal bleeding

Disadvantages:

• Symptom worsening first 2-4 weeks (irritation, possible retention - catheter 3-7 days common)
• Delayed improvement (maximal effect at 3 months)
• Less effective than TURP
• Durability beyond 5 years uncertain

Indications:

• Moderate LUTS
• Small-moderate prostates (less than 80g)
• Including median lobe
• Patient wants to avoid general anesthesia

Prostatic Artery Embolization (PAE)

Interventional radiology procedure - occlusion of prostatic arterial supply causing ischemic gland shrinkage.

Technique:

• Femoral artery access
• Selective catheterization of prostatic arteries (branches of internal iliac)
• Embolization with microspheres (300-500 microns)
• Bilateral embolization

Efficacy: [32]

• IPSS improvement: 30-50% reduction
• Prostate volume reduction: 20-30%
• Qmax improvement: Variable
• Durability: Emerging data (some re-growth/symptom recurrence)

Advantages:

• No general anesthesia
• Preserves ejaculatory function
• Can treat very large prostates

Disadvantages:

• Technical failure (5-10% - prostatic arteries not catheterizable)
• Post-embolization syndrome (pelvic pain, dysuria, hematuria, fever - common first week)
• Efficacy variable (depends on completeness of embolization)
• Risk of non-target embolization (bladder, rectum)
• Requires experienced interventional radiologist
• Limited long-term data

Indications:

• Research/selected centers
• Unfit for surgery
• Large prostates
• Anticoagulation

Trial Without Catheter (TWOC) After Acute Retention

Management of acute urinary retention: [33]

1. Immediate catheterization (urethral or suprapubic if urethral fails)
2. Drainage (measure residual volume)
3. Treat precipitant (if identifiable):
   • Constipation
   • Infection
   • Medications (anticholinergics, sympathomimetics)
   • Alcohol/excess fluids
   • Immobility
4. TWOC Protocol:
   • Catheter for 2-3 days (bladder rest)
   • Start α-blocker immediately (e.g., tamsulosin 400 mcg OD) - improves TWOC success by 30% [34]
   • Remove catheter (ideally morning, to allow daytime voiding attempts)
   • Monitor voiding (check PVR after first void)

Outcomes:

• TWOC Success: 50-70% (with α-blocker)
• Success Predictors: Younger age, smaller prostate, precipitant identified, residual volume less than 1L
• If TWOC fails: Surgical treatment (TURP/HoLEP) indicated

Long-term: Men with successful TWOC have ~50% risk of recurrent retention within 1 year → surgical treatment recommended.

---

11. Complications of BPH

Acute Urinary Retention (AUR)

Sudden painful inability to void despite full bladder.

Incidence: 3-4 per 1000 men aged 60-69 per year; 10 per 1000 in men > 80. [35]

Precipitants:

• No identifiable cause (spontaneous) - 50%
• Medications: Anticholinergics, antihistamines, decongestants (α-agonists), opiates
• Constipation
• Alcohol (diuresis + detrusor relaxation)
• Prolonged immobility (travel, bed rest)
• Post-operative (anesthesia, opiates, immobility)
• Infection

Presentation:

• Severe suprapubic pain
• Inability to pass urine (may pass small dribbles - overflow)
• Palpable tender bladder
• Agitation, distress

Management:

1. Urethral catheterization (14-16Fr):
   • Measure residual volume (typically 600-1500 mL)
   • Immediate relief
   • "Clamp-and-release" is unnecessary (historical myth that rapid drainage causes hematuria)
2. Suprapubic catheter if urethral fails (stricture, false passage)
3. Treat precipitant
4. Start α-blocker
5. TWOC after 2-3 days
6. Surgical referral if TWOC fails or recurrent AUR

Complications:

• Post-obstructive diuresis (rare after AUR; more common in chronic retention)
• Hematuria (venous decompression - usually settles)

Chronic Urinary Retention

Painless bladder distension with chronically elevated residual volume (> 300 mL).

Two subtypes with vastly different implications:

Low-Pressure Chronic Retention (LPCR)

• Large bladder capacity (often > 1L)
• Low intravesical pressure (detrusor failure)
• No hydronephrosis
• Normal renal function
• Asymptomatic or mild LUTS
• Overflow incontinence may occur (dribbling)

Management:

• Often asymptomatic (incidental finding)
• Medical therapy trial
• Surgery if symptomatic or worsening

High-Pressure Chronic Retention (HPCR)

Silent renal impairment - critical to recognize. [36]

Pathophysiology:

• Sustained high intravesical pressure (> 40 cmH₂O)
• Pressure exceeds ureteric peristaltic pressure
• Back-transmission to renal pelvis
• Bilateral hydronephrosis
• Progressive renal impairment (may present with CKD stage 4-5)

Presentation: (web/content/topics/bph-adult.mdx:1129)

• Painless (bladder desensitized)
• Palpable bladder (may reach umbilicus)
• Overflow incontinence (constant dribbling)
• Nocturnal enuresis (bed-wetting)
• Symptoms of renal failure: nausea, fatigue, pruritus, edema
• May present with acute-on-chronic retention (suddenly painful)

Investigations:

• Palpable bladder
• Elevated creatinine
• Bladder ultrasound: Massive residual (> 800-1500 mL)
• Renal ultrasound: Bilateral hydronephrosis

Management: (web/content/topics/bph-adult.mdx:1144)

⚠️ CRITICAL: This is a urological emergency.

1. Catheterize immediately (urethral or suprapubic)
   • Relieve obstruction
   • Do NOT clamp (continuous free drainage essential)
2. Admit to hospital (never send home immediately)
3. Monitor hourly urine output meticulously
4. Fluid balance chart
5. Watch for Post-Obstructive Diuresis:
   • Urine output > 200 mL/hr for 2 consecutive hours = significant diuresis
   • Pathophysiology: Renal tubules have lost concentrating ability (acquired nephrogenic DI)
   • Risk of hypovolemia, hypotension, shock
   • Electrolyte abnormalities: Hyponatremia, hypokalemia, hypomagnesemia
6. Replacement fluids:
   • Replace 50% of previous hour's urine output as IV normal saline (some use 0.45% saline)
   • Monitor U&Es twice daily
   • Continue until diuresis settles (usually 24-72h)
7. Urology referral: Surgical treatment (TURP/HoLEP) once renal function stabilized

Prognosis:

• Renal function may improve significantly post-decompression (if intervention early)
• Permanent CKD common if long-standing
• Some require long-term dialysis

Bladder Stones

Incidence: 5-8% of men with BPH

Pathophysiology:

• Chronic retention → urinary stasis
• Crystal precipitation (calcium oxalate, phosphate)
• Infection promotes struvite stones

Presentation:

• Intermittent stream ("ball-valve" effect)
• Terminal hematuria
• Suprapubic pain
• Recurrent UTIs
• Positional symptoms (worse standing, better lying)

Investigations:

• KUB X-ray: Most stones radio-opaque
• Bladder ultrasound: Echogenic focus with acoustic shadow
• Flexible cystoscopy: Direct visualization

Management:

1. Cystolitholapaxy (endoscopic stone fragmentation/removal)
2. TURP/HoLEP (simultaneously treat underlying BOO)

Recurrent Urinary Tract Infections

Chronic retention and residual urine → bacterial stasis → recurrent UTI.

Typical Organisms:

• E. coli (most common)
• Proteus (associated with stones)
• Enterococcus

Management:

• Treat acute infections
• Exclude stones (ultrasound)
• Definitive treatment of BOO (TURP/HoLEP) to eliminate residual urine

Hematuria

Mechanism:

• Enlarged prostate has rich venous plexus
• Friable vessels on prostatic urothelium
• Spontaneous bleeding (often after straining)

Assessment:

• Exclude malignancy (bladder cancer, kidney cancer, prostate cancer) - mandatory cystoscopy + CT urogram
• If BPH confirmed as source

Management:

• 5-ARI (finasteride/dutasteride) reduces vascularity - effective for recurrent hematuria
• TURP if refractory to 5-ARI

Obstructive Uropathy and Renal Impairment

Bilateral hydronephrosis from high-pressure chronic retention:

• Progressive renal failure (may be irreversible)
• See HPCR section above

---

12. Prognosis and Natural History

Natural History of Untreated BPH

Progressive condition in majority: [37]

• 30-40% stable symptoms over 5 years
• 30-40% gradual worsening (IPSS increases 1-2 points per year)
• 20-30% significant deterioration requiring intervention

Predictors of Progression: [38]

• Age > 70 years
• Prostate volume > 40g
• PSA > 1.5 ng/mL
• Qmax less than 10 mL/s
• PVR > 100 mL
• Moderate-severe LUTS (IPSS > 8)

Risk of Acute Urinary Retention:

• Without treatment: 1-2% per year
• With placebo in trials: 3-4% over 4 years

Prognosis After Treatment

Medical Therapy:

• Effective for symptom control in 60-70%
• Lifelong therapy required (symptoms return if stopped)
• 20-30% eventually require surgery (inadequate response or side effects)

Surgical Therapy (TURP/HoLEP):

• Excellent symptom relief: 70-85% improvement in IPSS
• Durable: 80-90% satisfaction at 5 years
• Re-operation rate: 10-20% at 10 years (recurrent adenoma growth)

MIST (UroLift, Rezum):

• Moderate symptom relief: 30-50% IPSS improvement
• Durability: Data to 5 years (some symptom recurrence)
• Re-treatment: Higher rates than TURP (~10-20% at 5 years)

---

13. Guidelines and Evidence

Key Guidelines

Landmark Trials

1. Medical Therapy of Prostatic Symptoms (MTOPS) [24]

• Design: RCT, N=3047, 4.5 years
• Intervention: Doxazosin vs. finasteride vs. combination vs. placebo
• Outcome: Clinical progression (AUR, renal insufficiency, incontinence, surgery)
• Results:
  • Combination therapy reduced progression by 66% (vs. 39% doxazosin, 34% finasteride)
  • Combination superior for symptom improvement
• Conclusion: Combination therapy most effective for preventing long-term progression

2. CombAT (Combination of Avodart and Tamsulosin Trial) [25]

• Design: RCT, N=4844, 4 years
• Intervention: Dutasteride + tamsulosin vs. monotherapy
• Inclusion: Prostate > 30g, PSA 1.5-10, IPSS ≥12
• Results:
  • Combination superior for IPSS improvement (-6.2 vs. -4.9 tamsulosin, -5.3 dutasteride)
  • Combination reduced AUR by 67% (vs. tamsulosin alone)
  • Greatest benefit in large prostates (> 40g)
• Conclusion: Combination therapy most effective in men with large prostates, high PSA

3. Saw Palmetto vs. Placebo for BPH (Cochrane Review) [26]

• Meta-analysis of RCTs
• Conclusion: Serenoa repens (saw palmetto) no more effective than placebo for LUTS
• Implication: Not recommended in guidelines

4. TURP vs. Watchful Waiting (Veterans Affairs Study) [42]

• Design: RCT, N=556, 5 years
• Results:
  • TURP provided greater symptom improvement
  • TURP associated with higher complication rates
  • No difference in mortality or renal function (most BPH does not cause renal failure)
• Conclusion: TURP effective but watchful waiting safe for mild-moderate LUTS

5. HoLEP vs. TURP (Multiple RCTs/Meta-analyses) [29]

• Results: HoLEP equivalent or superior to TURP for:
  • Symptom improvement
  • Flow rate improvement
  • Lower re-operation rates
  • Less bleeding
  • Shorter catheter time
• Conclusion: HoLEP excellent alternative, especially for large prostates

---

14. Examination Focus

Viva Questions and Model Answers

Q1: "A 68-year-old man presents with nocturia ×4, hesitancy, and weak stream. How would you assess him?"

Model Answer (web/content/topics/bph-adult.mdx:1344):

"I would take a comprehensive approach:

History:

• Characterize LUTS using storage, voiding, and post-micturition symptoms
• Assess severity and bother using the IPSS questionnaire (0-35 scale)
• Ask about red flags: hematuria, weight loss, bone pain, renal symptoms
• Exclude differentials: neurological history, previous urethral instrumentation, medications
• Enquire about fitness for surgery and patient preference

Examination:

• Abdominal: Palpable bladder (chronic retention?)
• Digital rectal exam: Assess prostate size, consistency, surface (smooth = BPH; hard/nodular = cancer)
• Neurological exam if indicated (saddle anesthesia, lower limb reflexes)

Investigations:

• Bedside: Urinalysis (exclude hematuria, infection); IPSS score; frequency-volume chart
• Blood: U&Es (renal function), PSA if appropriate (after counseling)
• Specialist: Uroflowmetry (Qmax), post-void residual (bladder ultrasound)

Management depends on severity, complications, and patient preference - ranging from watchful waiting to medical therapy (α-blockers ± 5-ARI) to surgery if refractory or complicated."

Q2: "What is high-pressure chronic retention and why is it dangerous?"

Model Answer (web/content/topics/bph-adult.mdx:1368):

"High-pressure chronic retention is a urological emergency where chronic bladder outlet obstruction causes sustained high intravesical pressure, leading to bilateral hydronephrosis and renal failure.

Pathophysiology:

• Bladder pressure exceeds ureteric peristaltic pressure (~40 cmH₂O)
• Back-pressure transmitted to renal pelvis
• Bilateral hydronephrosis
• Progressive CKD (may present with stage 4-5 renal failure)

Key Features:

• Painless (bladder desensitized) - unlike acute retention
• Palpable bladder (often massive, > 1L residual)
• Overflow incontinence
• Nocturnal enuresis
• Symptoms of renal failure: fatigue, nausea, edema

Danger: Silent progression to irreversible renal failure

Management:

1. Catheterize immediately (relieve obstruction)
2. Admit - never send home
3. Monitor urine output hourly (watch for post-obstructive diuresis > 200 mL/hr)
4. Replace fluids IV (50% of previous hour's output)
5. Daily U&Es (electrolyte abnormalities common)
6. Urology referral for definitive surgical treatment once stabilized"

Q3: "Explain the dual mechanism of bladder outflow obstruction in BPH and the rationale for combination therapy."

Model Answer (web/content/topics/bph-adult.mdx:1397):

"BPH causes obstruction through two distinct mechanisms, each contributing approximately 50%:

1. Static Component:

• Mechanical bulk of hyperplastic transition zone tissue
• Physical compression of prostatic urethra
• Median lobe may project into bladder neck ('ball-valve')

2. Dynamic Component:

• Prostatic smooth muscle (stroma) rich in α₁-adrenoceptors (predominantly α₁A subtype)
• Sympathetic nervous system activation → smooth muscle contraction
• Active constriction of prostatic urethra and bladder neck

Pharmacological Rationale:

α-Blockers (e.g., tamsulosin):

• Target dynamic component
• Block α₁-receptors → smooth muscle relaxation
• Rapid onset (days to weeks)
• Do NOT shrink prostate

5α-Reductase Inhibitors (e.g., finasteride, dutasteride):

• Target static component
• Block testosterone → DHT conversion
• Reduce prostate volume 20-30% over 6-12 months
• Slow onset (3-6 months)

Combination Therapy:

• Addresses both static AND dynamic components
• MTOPS and CombAT trials showed combination superior to monotherapy for:
  • Symptom improvement
  • Reducing risk of progression (AUR, need for surgery)
• Particularly beneficial in large prostates (> 40g), high PSA (> 1.5), moderate-severe LUTS"

Q4: "What is TUR syndrome and how has it been addressed in modern practice?"

Model Answer (web/content/topics/bph-adult.mdx:1431):

"TUR syndrome is a potentially life-threatening complication of monopolar TURP caused by systemic absorption of hypotonic irrigation fluid (glycine 1.5%) through opened prostatic venous sinuses.

Pathophysiology:

• Large volumes of hypotonic fluid absorbed (can be liters if prolonged resection)
• Dilutional hyponatremia (can drop to less than 120 mmol/L)
• Fluid overload (hypervolemia)
• Glycine toxicity (neurotransmitter effects, retinal toxicity)

Clinical Features:

• CNS: Confusion, agitation, visual disturbances (glycine effect), seizures, coma
• Cardiovascular: Hypertension (initially), then bradycardia, hypotension, arrhythmias, pulmonary edema
• Metabolic: Nausea, vomiting

Management:

• Recognition (intra-operative or within 24h post-op)
• Stop procedure if intra-operative
• Serum sodium (urgent)
• Hypertonic saline if severe (less than 120 mmol/L) + furosemide (if fluid overload)
• Supportive care: Monitor in HDU/ICU if severe

Modern Prevention:

• Bipolar TURP: Uses normal saline (0.9% NaCl) as irrigation fluid
  • Iso-osmotic → virtually eliminates TUR syndrome
  • Increasingly adopted as standard
• Limit resection time: Prolonged TURP (> 90 min) increases risk - consider staged procedure
• Alternative techniques: HoLEP (saline irrigation, laser energy)"

Q5: "A patient on tamsulosin for BPH is scheduled for cataract surgery. What specific concern arises and how should it be managed?"

Model Answer (web/content/topics/bph-adult.mdx:1461):

"The concern is Intraoperative Floppy Iris Syndrome (IFIS).

Pathophysiology:

• α₁A-Adrenoceptors present in iris dilator muscle
• Tamsulosin (highly α₁A-selective) causes irreversible changes to iris tone
• During cataract surgery:
  • Floppy, billowing iris (poor rigidity)
  • Progressive pupillary constriction despite mydriatics
  • Iris prolapse through surgical incisions

Clinical Impact:

• Significantly increases complication rates: posterior capsule rupture, vitreous loss
• Makes surgery technically challenging

Management Strategies:

Pre-operatively:

• ALWAYS ask about α-blockers before starting tamsulosin
• If cataract surgery planned within 6-12 months: Consider:
  • Delaying α-blocker until after eye surgery
  • Using alternative (5-ARI alone, or surgical referral)
  • Using less α₁A-selective agent (alfuzosin - though still some risk)

If patient already on tamsulosin:

• Inform ophthalmologist (critical communication)
• Stopping tamsulosin does NOT reverse changes (damage already done)
• Ophthalmologist prepares for IFIS:
  • Pupil expansion devices (Malyugin ring, iris hooks)
  • High-viscosity viscoelastic agents
  • Modified surgical technique

Conclusion: Prevention is key - careful history and communication between specialties."

MRCS/Urology Exam Pearls

High-Yield Facts (web/content/topics/bph-adult.mdx:1497):

1. BPH arises in transition zone (~5% normal volume, > 95% BPH); Cancer in peripheral zone (~70% normal, ~70% cancer)
2. DHT is 10x more potent than testosterone; produced by 5α-reductase type 2
3. IPSS 0-7 mild, 8-19 moderate, 20-35 severe - know these thresholds
4. Qmax > 15 normal, less than 10 obstructed (assuming voided volume > 150ml)
5. α-blockers: Fast (days), target dynamic component, retrograde ejaculation 5-10%, IFIS risk
6. 5-ARIs: Slow (3-6 months), shrink gland 20-30%, halve PSA, sexual SEs, teratogenic
7. Combination therapy: MTOPS/CombAT trials - 66% reduction in progression
8. TURP: Gold standard, 70% IPSS improvement, retrograde ejaculation 65-75%, TUR syndrome (monopolar)
9. HoLEP: Better for large glands (> 80-100g), lower re-operation rate, steep learning curve
10. UroLift: Preserves ejaculation (~90%), only for no median lobe, moderate efficacy
11. HPCR: Painless retention, bilateral hydronephrosis, renal failure, post-obstructive diuresis > 200ml/hr
12. Post-obstructive diuresis management: Replace 50% of previous hour's output IV
13. TWOC: α-blocker improves success by 30%, catheter 2-3 days
14. AUR annual incidence: 3-4 per 1000 (age 60-69), 10 per 1000 (> 80)
15. Lifetime risk of surgery: 20-30%

---

15. Patient and Layperson Explanation

What is the prostate?

The prostate is a small gland about the size of a walnut that sits just below the bladder in men. Its main job is to produce some of the fluid that makes up semen. The tube that carries urine from your bladder (the urethra) runs right through the middle of the prostate.

Why does it cause problems?

As men get older, the prostate naturally tends to grow - this is called benign prostatic hyperplasia or BPH ("benign" means it's not cancer). By age 60, about half of men have some prostate enlargement, and by age 85, about 9 out of 10 men are affected.

Because the urine tube runs through the prostate, when the gland gets bigger, it can squeeze the tube and make it harder to pass urine. Think of it like a garden hose with someone standing on it - the water flow slows down.

What symptoms might I notice?

The symptoms fall into a few categories:

Difficulty with urination:

• Taking a long time to start urinating (hesitancy)
• Weak stream - urine comes out slowly
• Having to strain or push
• The stream stops and starts (intermittency)
• Feeling like your bladder hasn't completely emptied

Frequent trips to the bathroom:

• Needing to urinate often during the day (frequency)
• Having to get up at night to urinate (nocturia)
• Sudden, urgent need to urinate

After urinating:

• Dribbling after you think you've finished

Is this cancer?

No. "Benign" means it's NOT cancer. BPH is a natural part of aging and is completely separate from prostate cancer, though some men can have both conditions. Your doctor might check your PSA (prostate-specific antigen) blood test to help make sure there are no signs of cancer.

What are the treatment options?

Treatment depends on how much the symptoms bother you:

1. Watchful Waiting (if symptoms are mild):

• Making simple lifestyle changes:
  • Drink less fluid in the evening (to reduce nighttime trips)
  • Reduce caffeine and alcohol (these irritate the bladder)
  • Try "double voiding"
• urinate, wait a minute, then try again

2. Medication (if symptoms are moderate to severe):

Two main types of tablets:

• Alpha-blockers (like tamsulosin): These relax the muscles in the prostate and bladder neck, making it easier to urinate. They work within a few days but can cause dizziness and affect ejaculation.

• 5-alpha-reductase inhibitors (like finasteride): These actually shrink the prostate over time (by about 20-30%). They take 3-6 months to work and can affect sexual function.

• Sometimes both types are used together for better results.

3. Surgery (if medication doesn't work or complications develop):

Several options exist:

• TURP (transurethral resection of the prostate): The traditional "gold standard" operation done through the urethra using a special telescope - no cuts on your skin. The surgeon removes the excess prostate tissue that's blocking the flow. Most men have excellent relief of symptoms, but it can affect ejaculation (semen goes backward into the bladder - this is harmless but can affect fertility).

• HoLEP (laser surgery): Similar results to TURP, particularly good for very large prostates, with less bleeding.

• Minimally invasive options (UroLift, Rezum): Newer techniques done as day-case procedures. Less invasive but may not be as effective as TURP for severe symptoms.

What happens if I don't get treatment?

For some men, symptoms remain stable or improve on their own. But BPH is usually a progressive condition - symptoms tend to worsen over time. Potential complications include:

• Urinary retention: Suddenly being unable to urinate at all (very painful) - this needs emergency catheter insertion
• Bladder damage: The bladder muscle can weaken over time from working against the obstruction
• Kidney problems: Rarely, severe obstruction can cause back-pressure on the kidneys
• Bladder stones: Urine stagnation can cause stones to form
• Recurrent infections: Stagnant urine increases infection risk

What should I do?

Talk to your doctor. They'll assess your symptoms (often using a questionnaire), examine you (including examining the prostate through the back passage), and may arrange some tests. Together, you can decide on the best treatment plan based on how much your symptoms bother you and how they affect your quality of life.

Remember, BPH is not cancer, and there are effective treatments available. Many men live with mild BPH symptoms without needing treatment, while others benefit greatly from medication or surgery.

---

16. References

Primary Sources

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132(3):474-479. DOI: 10.1016/s0022-5347(17)49698-4

2. Roehrborn CG. Benign prostatic hyperplasia: an overview. Rev Urol. 2005;7 Suppl 9(Suppl 9):S3-S14. PMID: 16985902

3. Abrams P. New words for old: lower urinary tract symptoms for "prostatism". BMJ. 1994;308(6934):929-930. DOI: 10.1136/bmj.308.6934.929

4. McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185(5):1793-1803. DOI: 10.1016/j.juro.2011.01.074

5. Gravas S, Cornu JN, Gacci M, et al. EAU Guidelines on Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). European Association of Urology. 2024. Available at: https://uroweb.org/guidelines/non-neurogenic-male-luts

6. Platz EA, Joshu CE, Mondul AM, et al. Incidence and progression of lower urinary tract symptoms in a large prospective cohort of United States men. J Urol. 2012;188(2):496-501. DOI: 10.1016/j.juro.2012.03.125

7. Parsons JK, Bergstrom J, Silberstein J, Barrett-Connor E. Prevalence and characteristics of lower urinary tract symptoms in men aged > or = 80 years. Urology. 2008;72(2):318-321. DOI: 10.1016/j.urology.2008.03.057

8. Parsons JK. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems. J Urol. 2007;178(2):395-401. DOI: 10.1016/j.juro.2007.03.103

9. Gacci M, Corona G, Vignozzi L, et al. Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis. BJU Int. 2015;115(1):24-31. DOI: 10.1111/bju.12728

10. Russell DW, Wilson JD. Steroid 5 alpha-reductase: two genes/two enzymes. Annu Rev Biochem. 1994;63:25-61. DOI: 10.1146/annurev.bi.63.070194.000325

11. Nicholson TM, Ricke WA. Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation. 2011;82(4-5):184-199. DOI: 10.1016/j.diff.2011.04.006

12. McNeal JE. The zonal anatomy of the prostate. Prostate. 1981;2(1):35-49. DOI: 10.1002/pros.2990020105

13. Lepor H. Pathophysiology of lower urinary tract symptoms in the aging male population. Rev Urol. 2005;7 Suppl 7(Suppl 7):S3-S11. PMID: 16985874

14. Oelke M, Bachmann A, Descazeaud A, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013;64(1):118-140. DOI: 10.1016/j.eururo.2013.03.004

15. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167-178. DOI: 10.1002/nau.10052

16. Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148(5):1549-1557. DOI: 10.1016/s0022-5347(17)36966-5

17. Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol. 2006;49(4):651-658. DOI: 10.1016/j.eururo.2006.02.018

18. Wolf AM, Wender RC, Etzioni RB, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010;60(2):70-98. DOI: 10.3322/caac.20066

19. Rosier PF, Schaefer W, Lose G, et al. International Continence Society Good Urodynamic Practices and Terms 2016: Urodynamics, uroflowmetry, cystometry, and pressure-flow study. Neurourol Urodyn. 2017;36(5):1243-1260. DOI: 10.1002/nau.23124

20. Emberton M, Fitzpatrick JM, Rees J. Risk stratification for benign prostatic hyperplasia (BPH) treatment. BJU Int. 2011;107(6):876-880. DOI: 10.1111/j.1464-410X.2010.09946.x

21. Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol. 1999;36(1):1-13. DOI: 10.1159/000019919

22. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387-2398. DOI: 10.1056/NEJMoa030656

23. Traish AM, Haider KS, Doros G, Haider A. Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction. Horm Mol Biol Clin Investig. 2017;30(3). DOI: 10.1515/hmbci-2017-0015

24. McConnell JD, Roehrborn CG, Bautista OM, et al; Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387-2398. DOI: 10.1056/NEJMoa030656

25. Roehrborn CG, Siami P, Barkin J, et al; CombAT Study Group. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123-131. DOI: 10.1016/j.eururo.2009.09.035

26. Tacklind J, MacDonald R, Rutks I, Wilt TJ. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2012;12:CD001423. DOI: 10.1002/14651858.CD001423.pub3

27. Madersbacher S, Alivizatos G, Nordling J, et al. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol. 2004;46(5):547-554. DOI: 10.1016/j.eururo.2004.07.016

28. Ahyai SA, Gilling P, Kaplan SA, et al. Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol. 2010;58(3):384-397. DOI: 10.1016/j.eururo.2010.06.005

29. Yin L, Teng J, Huang CJ, Zhang X, Xu D. Holmium laser enucleation of the prostate versus transurethral resection of the prostate: a systematic review and meta-analysis of randomized controlled trials. J Endourol. 2013;27(5):604-611. DOI: 10.1089/end.2012.0505

30. Roehrborn CG, Gange SN, Shore ND, et al. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study. J Urol. 2013;190(6):2161-2167. DOI: 10.1016/j.juro.2013.05.116

31. McVary KT, Rogers T, Roehrborn CG. Rezūm Water Vapor Thermal Therapy for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: 4-Year Results From Randomized Controlled Study. Urology. 2019;126:171-179. DOI: 10.1016/j.urology.2018.12.041

32. Carnevale FC, Antunes AA. Prostatic artery embolization for enlarged prostates due to benign prostatic hyperplasia. How I do it. Cardiovasc Intervent Radiol. 2013;36(6):1452-1463. DOI: 10.1007/s00270-013-0680-5

33. Djavan B, Madersbacher S, Klingler C, et al. Urodynamic assessment of patients with acute urinary retention: is treatment failure after prostatectomy predictable? J Urol. 1997;158(5):1829-1833. DOI: 10.1016/s0022-5347(01)64140-6

34. McNeill SA, Hargreave TB; Alfaur Study Group. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. J Urol. 2004;171(6 Pt 1):2316-2320. DOI: 10.1097/01.ju.0000127753.01670.7f

35. Jacobsen SJ, Jacobson DJ, Girman CJ, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol. 1997;158(2):481-487. DOI: 10.1016/s0022-5347(01)64508-7

36. George NJ, O'Reilly PH, Barnard RJ, Blacklock NJ. High pressure chronic retention. Br Med J. 1983;286(6380):1780-1783. DOI: 10.1136/bmj.286.6380.1780

37. Bosch JL, Bangma CH, Groeneveld FP, Bohnen AM. The long-term relationship between a real change in prostate volume and a significant change in lower urinary tract symptom severity in population-based men: the Krimpen study. Eur Urol. 2008;53(4):819-825. DOI: 10.1016/j.eururo.2007.08.042

38. Crawford ED, Wilson SS, McConnell JD, et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol. 2006;175(4):1422-1426. DOI: 10.1016/S0022-5347(05)00683-6

39. National Institute for Health and Care Excellence (NICE). Lower urinary tract symptoms in men: management. Clinical guideline [CG97]. Published May 2010, updated 2015. Available at: https://www.nice.org.uk/guidance/cg97

40. European Association of Urology. EAU Guidelines on Non-Neurogenic Male LUTS. 2024 edition. Available at: https://uroweb.org/guidelines/non-neurogenic-male-luts

41. American Urological Association. Surgical Management of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms (2021, amended 2023). Available at: https://www.auanet.org/guidelines-and-quality/guidelines/benign-prostatic-hyperplasia-(bph)-guideline

42. Wasson JH, Reda DJ, Bruskewitz RC, et al. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. N Engl J Med. 1995;332(2):75-79. DOI: 10.1056/NEJM199501123320202

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference only. Clinical decisions must account for individual patient circumstances, local protocols, and current evidence. Always consult appropriate specialists and follow local guidelines. This content does not replace clinical judgment or formal medical training.